ArticlePharmacoEconomics2022

Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US.

Hardik Goswami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.